JNJ's lockup wrt ACHN shares expired in June 2017—i.e. “sixty days after the first public announcement of top-line clinical results from Janssen’s phase IIb OMEGA-1 clinical trial” [emphasis added]. JNJ reported the top-line results on 4/27/17 (#msg-130712374).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.